Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations
Oil Prices Surge Over 3% as Trump Rejects Iran Peace Response
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says
S&P 500, Nasdaq Hit Record Highs as AI Stocks Rally and Strong Jobs Data Boost Confidence
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases
Australia Budget 2026: Smaller Deficit Expected Amid Tax Reform Push 



